Our results seem to confirm that hzVSF-v13 may offer a synergistic advantage as compared with other treatments that do not target vimentin, as vimentin has a twofold role in the disease, both in viral infection and in the associated life-threatening lung inflammation. Here, IGLV2-11 is linked to inflammatory response.